Showing results (1411-1420 of 1,689) with videos related to
Sort By:
Pageof 169
ESC Heart Failure|September 27, 2024
Guideline-directed medical therapy implementation during hospitalization for cardiogenic shockMatthew G Dimond, Carolyn M Rosner, Seiyon Ben Lee, et al.Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|July 23, 2026
Correction: Transplantation of older DCD livers in the machine perfusion era: a U.S. cohort studyEmmanouil Giorgakis, Ioannis A Ziogas, Dimitrios Moris, et al.Journal of the American College of Cardiology|January 15, 2025
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFShingo Matsumoto, Pardeep S Jhund, Alasdair D Henderson, et al.JAMA Cardiology|November 17, 2024
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Xiaowen Wang, Pardeep S Jhund, et al.European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.Cell Host & Microbe|March 21, 2024
Opposing diet, microbiome, and metabolite mechanisms regulate inflammatory bowel disease in a genetically susceptible hostGabriel Vasconcelos Pereira, Marie Boudaud, Mathis Wolter, et al.Pageof 169